Evotech has appointed Dr. Ashiq Khan as Chief Commercial Officer, putting the executive with experience in robotics and artificial intelligence in charge of a division central to the company’s recently announced transformation plan.
Last month, the biopharmaceutical service provider listed commercial enforcement as one of three focuses of its restructuring. Evotec will be closing its site and laying off staff as part of the changes. However, on a conference call regarding the reorganization, Evotec CEO Christian Wojciechowski told investors that the company is expanding its commercial organization and upgrading its management team to become more responsive to customers.
At the time, Woczewski said Evotech had already hired several people and was working on additional appointments. Khan’s is the highest-profile appointment to date. As head of the commercial group, Mr. Khan will lead the creation of a global organization aligned with Evotec’s capabilities.
Mr. Woczewski said in a statement that Mr. Khan has been driving growth in robotics, AI and drug discovery platforms, adding that his expertise will be essential to executing Evotech’s transformation. Mr. Wojczewski expects Mr. Khan to recognize and create new opportunities for Evotec as the company aims to build a drug discovery and development engine centered around high-value services and capabilities.
Khan previously served as chief business officer at Ictos, an AI-driven drug discovery company, and joined the company in September. Earlier in his career, Kahn held senior leadership roles at Proteros Bio Structures and Schrödinger.
Wojczewski said the new leadership is inheriting the organization and is already feeling the benefits of recent changes. Evotech’s chief executive officer said last month that initiatives such as efforts to accelerate response to requests for proposals are bearing fruit, with the number of leads increasing and sales stable. Mr Woczewski added that momentum for strategic deals is increasing.
Evotec needs the deal to combat weak demand for its discovery and preclinical services and reverse a decline in revenue, which fell 7.1% in the first nine months of 2025. To surpass the sales the company will generate in 2024, it will need to hit a full-year high when it releases next week’s results.
